scispace - formally typeset
M

Michael D. Prados

Researcher at University of California, San Francisco

Publications -  466
Citations -  57545

Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.

Papers
More filters
Journal ArticleDOI

A comparison of CT contrast enhancement and BUDR labeling indices in moderately and highly anaplastic astrocytomas of the cerebral hemispheres.

TL;DR: Comparison enhancement on CT scans does not always correctly predict proliferative potential in these tumors, and biopsy and labeling studies are recommended before therapy, according to the bromodeoxyuridine (BUDR) labeling index (LI).
Journal ArticleDOI

Automated tumor segmentation and brain tissue extraction from multiparametric MRI of pediatric brain tumors: A multi-institutional study

TL;DR: In this article , a multi-institutional deep learning-based method for automated brain extraction and segmentation of pediatric brain tumors based on multi-parametric MRI scans is presented, which can facilitate detection of abnormal regions for further clinical measurements.
Journal ArticleDOI

Lab-experimental (pre-clinical) therapeutics and pharmacology

Fa H. Yang, +330 more
- 01 Oct 2012 - 
TL;DR: Rg3-NPs may be a potent cell-cycle regulation drug targeting the M-phase in glioblastoma cell lines and induced the expression of the apoptotic and antimigratory protein p53 in cell lines.
Journal ArticleDOI

Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas

TL;DR: The pharmacokinetics of vemurafenib in pediatric patients with recurrent/refractory astrocytomas harboring the BRAFV600E mutation was characterized and a 1-compartment model with first-order absorption and elimination was developed, which adequately described the PK in children between a wide age range of 3 to 19 years old.